Loading... Please wait...
Sort by:

 

firstview-jpg.jpgFirstView reports deliver unique insight into current and future pharma market dynamics through quantitative surveys with physicians. With the ability to query a 1-million strong online physician community worldwide, FirstView provides essential data to support effective decision making in major disease areas and on key industry issues.

  • Market Access Impact: HIV (EU5)
    Learn More Market Access Impact: HIV (EU5)
    Can prescription barriers help the 2nd and 3rd place HIV brands catch up to the runaway market leader? In the European HIV treatment market, the leading brand is comfortably ahead—but can market barriers help...
  • Market Access Impact: Psoriasis (US)
    Learn More Market Access Impact: Psoriasis (US)
    See how formularies, reimbursement, and price are ensuring the disparity in market share among brands In the psoriasis market, brands are gaining or losing market share to the competition due to the effects of market...
  • Market Access Impact: Psoriasis (EU5)
    Learn More Market Access Impact: Psoriasis (EU5)
    Price and reimbursement are stopping physicians from prescribing the drugs they want.  In the psoriasis market, brands are gaining or losing market share due to, in many cases, avoidable barriers. There's a clear...
  • Medical Affairs Reputations Non-small Cell Lung Cancer (EU5)
    Learn More Medical Affairs Reputations Non-small Cell Lung Cancer (EU5)
    Four medical affairs teams battling it out for top spot. How does your team compare? In the fiercely competitive European non-small cell lung cancer (NSCLC) treatment market, one medical affairs team leads. But for how...
  • Medical Affairs Reputations Non-small Cell Lung Cancer (US)
    Learn More Medical Affairs Reputations Non-small Cell Lung Cancer (US)
    Top medical affairs team safely ahead, but competition for 2nd and 3rd place is fierce In the US non-small cell lung cancer (NSCLC) treatment market, competition among medical affairs teams is fierce. The top team may...
  • Medical Affairs Reputations: Psoriasis (US)
    Learn More Medical Affairs Reputations: Psoriasis (US)
    One brand’s medical affairs team scores 30% higher than any other. Can your team catch up? Ranked for overall quality of interactions, the leading medical affairs team in the US psoriasis treatment market beats...
  • Medical Affairs Reputations: Psoriasis (EU5)
    Learn More Medical Affairs Reputations: Psoriasis (EU5)
    Who has the best medical affairs team? In Europe, two brands dominate Two medical affairs teams are fighting it out for top spot in the European psoriasis treatment market—and leaving the rest of the pack far...
  • Market Access Impact: Melanoma (EU5)
    Learn More Market Access Impact: Melanoma (EU5)
    Compare 7 leading melanoma drugs. See why the 2nd-place brand is closing in on the top player When oncologists can’t prescribe the drugs they want, brands lose market share—share that goes to the competition...
  • Market Access Impact: Melanoma (US)
    Learn More Market Access Impact: Melanoma (US)
    Compare 7 leading melanoma drugs. Find out how lower-ranked rivals are threatening top brands When oncologists can’t prescribe the drugs they want, brands lose market share—share that goes to the competition...
  • Medical Affairs Reputations: Rheumatoid Arthritis (EU5)
    Learn More Medical Affairs Reputations: Rheumatoid Arthritis (EU5)
    Is your rheumatoid arthritis Medical Affairs team leading the pack or following behind?  How well are the Medical Affairs teams from biosimilar manufacturers performing when compared with those from...
  • Medical Affairs Reputations: Rheumatoid Arthritis (US)
    Learn More Medical Affairs Reputations: Rheumatoid Arthritis (US)
    Is your rheumatoid arthritis Medical Affairs team leading the pack or following on behind? How are Medical Affairs teams from challenger brands shaping up when compared with those from well-established products in the...
  • Medical Affairs Reputations: Asthma/COPD (EU5)
    Learn More Medical Affairs Reputations: Asthma/COPD (EU5)
    How well does your Asthma/COPD medical affairs team compare with your rivals in Europe? Which brand's medical affairs team is perceived to be the best and which is the worst? Who scored almost 5 times better on the...
  • Medical Affairs Reputations: Asthma/COPD (US)
    Learn More Medical Affairs Reputations: Asthma/COPD (US)
    How well does your Asthma/COPD medical affairs team compare with your rivals in the US? Which brand's medical affairs team is perceived to be the best and which is the worst? Who scored almost 5 times better on the...
  • Market Access Impact: Asthma/COPD (EU5)
    Learn More Market Access Impact: Asthma/COPD (EU5)
    Are prescribing constraints costing your brand market share? Doctors can’t always prescribe the asthma/COPD drugs they want to prescribe. The reason: market barriers—things like pricing, reimbursement,...
  • Market Access Impact: Asthma/COPD (US)
    Learn More Market Access Impact: Asthma/COPD (US)
    Are prescribing constraints costing your brand market share? Doctors can’t always prescribe the asthma/COPD drugs they want to prescribe. The reason: market barriers—things like pricing, reimbursement,...
  • Medical Affairs Reputations (EU5): Type 2 Diabetes Mellitus
    Learn More Medical Affairs Reputations (EU5): Type 2 Diabetes Mellitus
    What do physicians think of Europe Medical Affairs teams in the Type 2 Diabetes Mellitus (T2DM) sector? Who gets top marks for performance and reputation? Who fails to measure up? How is your Medical Affairs team...

customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved